Header Logo

Connection

Ajaypal Singh to Male

Back to Details
This is a "connection" page, showing publications Ajaypal Singh has written about Male.
Ajaypal Singh
Connection Strength
1.484
Male
  1. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
    View in: PubMed
    Score: 0.066
  2. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
    View in: PubMed
    Score: 0.064
  3. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
    View in: PubMed
    Score: 0.064
  4. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
    View in: PubMed
    Score: 0.062
  5. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
    View in: PubMed
    Score: 0.062
  6. Occupational risk factors for chronic kidney disease in Andhra Pradesh: 'Uddanam Nephropathy'. Ren Fail. 2020 Nov; 42(1):1032-1041.
    View in: PubMed
    Score: 0.058
  7. Necrotizing fasciitis of the lower extremity: imaging pearls and pitfalls. Br J Radiol. 2018 Jul; 91(1088):20180093.
    View in: PubMed
    Score: 0.048
  8. Imaging of abdominal and pelvic injuries from the Boston Marathon bombing. Emerg Radiol. 2016 Feb; 23(1):35-39.
    View in: PubMed
    Score: 0.041
  9. Head and neck injuries from the Boston Marathon bombing at four hospitals. Emerg Radiol. 2015 Oct; 22(5):527-32.
    View in: PubMed
    Score: 0.039
  10. Predictors of renal replacement therapy and mortality in children with chronic kidney disease. Saudi Med J. 2015 Jan; 36(1):32-9.
    View in: PubMed
    Score: 0.038
  11. Radiologic features of injuries from the Boston Marathon bombing at three hospitals. AJR Am J Roentgenol. 2014 Aug; 203(2):235-9.
    View in: PubMed
    Score: 0.037
  12. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013 May 28; 14:114.
    View in: PubMed
    Score: 0.034
  13. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013 Mar; 22(2):198-203.
    View in: PubMed
    Score: 0.034
  14. Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. Clin Appl Thromb Hemost. 2012 Sep; 18(5):453-61.
    View in: PubMed
    Score: 0.032
  15. Is there a deleterious effect of erythropoietin in end-stage renal disease? Kidney Int. 2011 Sep; 80(6):569-71.
    View in: PubMed
    Score: 0.031
  16. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010 Feb; 77(3):239-46.
    View in: PubMed
    Score: 0.027
  17. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009 May; 53(5):751-9.
    View in: PubMed
    Score: 0.026
  18. Core biopsy with curved needle technique. AJR Am J Roentgenol. 2008 Dec; 191(6):1745-50.
    View in: PubMed
    Score: 0.025
  19. Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract. 2008; 110(4):c244-50.
    View in: PubMed
    Score: 0.025
  20. Emergency MRI of acute pelvic pain: MR protocol with no oral contrast. Emerg Radiol. 2009 Mar; 16(2):133-41.
    View in: PubMed
    Score: 0.025
  21. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 Sep; 74(6):791-8.
    View in: PubMed
    Score: 0.025
  22. Neoplastic iliopsoas masses in oncology patients: CT findings. Abdom Imaging. 2008 Jul-Aug; 33(4):493-7.
    View in: PubMed
    Score: 0.025
  23. De novo multifocal renal cell carcinoma in the renal allograft. Kidney Int. 2009 Jan; 75(1):111-4.
    View in: PubMed
    Score: 0.024
  24. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 Sep; 74(6):782-90.
    View in: PubMed
    Score: 0.024
  25. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 2008 Dec; 74(12):1617-22.
    View in: PubMed
    Score: 0.024
  26. Acute coronary syndrome in ESRD patients. Kidney Int. 2009 Mar; 75(5):558-62.
    View in: PubMed
    Score: 0.024
  27. Dropped appendicolith: CT findings and implications for management. AJR Am J Roentgenol. 2008 Mar; 190(3):707-11.
    View in: PubMed
    Score: 0.024
  28. Prevention of intravenous contrast-induced nephropathy in hospital inpatients. Crit Pathw Cardiol. 2008 Mar; 7(1):1-4.
    View in: PubMed
    Score: 0.024
  29. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract. 2007 May-Jun; 13(3):251-9.
    View in: PubMed
    Score: 0.023
  30. Imaging-guided catheter drainage of abdominal collections with fistulous pancreaticobiliary communication. AJR Am J Roentgenol. 2006 Dec; 187(6):1591-6.
    View in: PubMed
    Score: 0.022
  31. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16; 355(20):2085-98.
    View in: PubMed
    Score: 0.022
  32. Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. Transplantation. 2006 Sep 15; 82(5):612-8.
    View in: PubMed
    Score: 0.022
  33. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis. 2004 Dec; 44(6):1050-9.
    View in: PubMed
    Score: 0.019
  34. CT appearance of acute appendagitis. AJR Am J Roentgenol. 2004 Nov; 183(5):1303-7.
    View in: PubMed
    Score: 0.019
  35. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis. 2004 May; 43(5):772-81.
    View in: PubMed
    Score: 0.018
  36. Omental infarct: an unusual CT appearance after superior mesenteric artery occlusion. Emerg Radiol. 2004 Apr; 10(5):276-8.
    View in: PubMed
    Score: 0.018
  37. Imaging of inflammatory bowel disease: CT and MR. Dig Dis. 2004; 22(1):56-62.
    View in: PubMed
    Score: 0.018
  38. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol. 2003 Oct; 14(10):2573-80.
    View in: PubMed
    Score: 0.018
  39. Accuracy and timeliness of an abbreviated emergency department MRCP protocol for choledocholithiasis. Emerg Radiol. 2019 Aug; 26(4):427-432.
    View in: PubMed
    Score: 0.013
  40. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 05; 21(5):1199-1208.
    View in: PubMed
    Score: 0.013
  41. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
    View in: PubMed
    Score: 0.013
  42. The Prevalence, Clinical Spectrum and the Long Term Outcome of ST-segment Elevation Myocardial Infarction in Young - A Prospective Observational Study. Cardiovasc Revasc Med. 2019 05; 20(5):387-391.
    View in: PubMed
    Score: 0.012
  43. The added value of cross-sectional imaging in the detection of additional radiographically occult fractures in the setting of a Chopart fracture. Emerg Radiol. 2018 Oct; 25(5):513-520.
    View in: PubMed
    Score: 0.012
  44. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol. 2017; 46(6):488-497.
    View in: PubMed
    Score: 0.012
  45. BP in Dialysis: Results of a Pilot Study. J Am Soc Nephrol. 2018 01; 29(1):307-316.
    View in: PubMed
    Score: 0.012
  46. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017; 46(5):364-370.
    View in: PubMed
    Score: 0.012
  47. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type?2 Diabetic Patients With CKD. Am J Kidney Dis. 2017 Oct; 70(4):522-531.
    View in: PubMed
    Score: 0.011
  48. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2016 Dec; 68(6):873-881.
    View in: PubMed
    Score: 0.011
  49. Prevalence of Hyperparathyroidism, Mineral and Bone Disorders in Children with Advanced Chronic Kidney Disease. Indian J Pediatr. 2016 May; 83(5):420-5.
    View in: PubMed
    Score: 0.010
  50. Ferric pyrophosphate citrate (Triferic?) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 2015 Dec; 30(12):2019-26.
    View in: PubMed
    Score: 0.010
  51. Cognitive function and all-cause mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2015 Feb; 65(2):303-11.
    View in: PubMed
    Score: 0.009
  52. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
    View in: PubMed
    Score: 0.009
  53. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013 Jan 29; 80(5):471-80.
    View in: PubMed
    Score: 0.008
  54. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
    View in: PubMed
    Score: 0.008
  55. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
    View in: PubMed
    Score: 0.008
  56. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55.
    View in: PubMed
    Score: 0.007
  57. Rapidly deteriorating kidney function in a young man previously diagnosed with membranous nephropathy. Nephron Clin Pract. 2010; 115(2):c100-6.
    View in: PubMed
    Score: 0.007
  58. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant. 2010 May; 25(5):1567-75.
    View in: PubMed
    Score: 0.007
  59. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
    View in: PubMed
    Score: 0.007
  60. Disclosure of the HIV infection status in children. Indian J Pediatr. 2009 Aug; 76(8):805-8.
    View in: PubMed
    Score: 0.007
  61. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis. 2009 Sep; 54(3):498-510.
    View in: PubMed
    Score: 0.007
  62. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
    View in: PubMed
    Score: 0.007
  63. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008 Feb; 19(2):372-9.
    View in: PubMed
    Score: 0.006
  64. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol. 2007 Dec; 18(12):3184-91.
    View in: PubMed
    Score: 0.006
  65. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007 Mar; 18(3):975-84.
    View in: PubMed
    Score: 0.006
  66. Associations between demographic factors and provider structures on cost and length of stay for hemodialysis patients with vascular access failure. Clin J Am Soc Nephrol. 2006 May; 1(3):455-61.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.